Literature DB >> 28881388

Autosomal dominant calpainopathy due to heterozygous CAPN3 C.643_663del21.

Jennifer M Martinez-Thompson1, Zhiyv Niu2,3, Jennifer A Tracy1, Steven A Moore4, Andrea Swenson5, Eric D Wieben6, Margherita Milone1.   

Abstract

INTRODUCTION: A calpain-3 (CAPN3) gene heterozygous deletion (c.643_663del21) was recently linked to autosomal dominant (AD) limb-girdle muscular dystrophy. However, the possibility of digenic disease was raised. We describe 3 families with AD calpainopathy carrying this isolated mutation.
METHODS: Probands heterozygous for CAPN3 c.643_663del21 were identified by targeted next generation or whole exome sequencing. Clinical findings were collected for probands and families. Calpain-3 muscle Western blots were performed in 3 unrelated individuals.
RESULTS: Probands reported variable weakness in their 40s or 50s, with myalgia, back pain, or hyperlordosis. Pelvic girdle muscles were affected with adductor and hamstring sparing. Creatine kinase was normal to 1,800 U/L, independent of weakness severity. Imaging demonstrated lumbar paraspinal muscle atrophy. Electromyographic findings and muscle biopsies were normal to mildly myopathic. Muscle calpain-3 expression was reduced. DISCUSSION: This study provides further evidence for AD calpainopathy associated with CAPN3 c.643_663del21. No pathogenic variants in other genes known to cause myopathy were detected. Muscle Nerve 57: 679-683, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CAPN3; autosomal dominant myopathy; axial myopathy; limb-girdle muscular dystrophy

Mesh:

Substances:

Year:  2017        PMID: 28881388      PMCID: PMC5915624          DOI: 10.1002/mus.25970

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  A family with McLeod syndrome and calpainopathy with clinically overlapping diseases.

Authors:  A Starling; D Schlesinger; F Kok; M Rita Passos-Bueno; M Vainzof; M Zatz
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

Review 2.  Limb-girdle muscular dystrophy 2A.

Authors:  Eduard Gallardo; Amets Saenz; Isabel Illa
Journal:  Handb Clin Neurol       Date:  2011

3.  Reply: Dominant LGMD2A: alternative diagnosis or hidden digenism?

Authors:  John Vissing; Morten Duno
Journal:  Brain       Date:  2016-11-15       Impact factor: 13.501

4.  Clinical Reasoning: A 30-year-old man with progressive weakness and atrophy.

Authors:  Colin Quinn; Steven A Moore; Tanya M Bardakjian; Chafic Karam
Journal:  Neurology       Date:  2016-11-08       Impact factor: 9.910

5.  Mutations in calpain 3 associated with limb girdle muscular dystrophy: analysis by molecular modeling and by mutation in m-calpain.

Authors:  Z Jia; V Petrounevitch; A Wong; T Moldoveanu; P L Davies; J S Elce; J S Beckmann
Journal:  Biophys J       Date:  2001-06       Impact factor: 4.033

6.  Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle.

Authors:  Yanchao Huang; Antoine de Morrée; Alexandra van Remoortere; Kate Bushby; Rune R Frants; Johan T den Dunnen; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2008-03-11       Impact factor: 6.150

7.  Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A.

Authors:  I Richard; O Broux; V Allamand; F Fougerousse; N Chiannilkulchai; N Bourg; L Brenguier; C Devaud; P Pasturaud; C Roudaut
Journal:  Cell       Date:  1995-04-07       Impact factor: 41.582

8.  A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy.

Authors:  John Vissing; Rita Barresi; Nanna Witting; Marijke Van Ghelue; Lise Gammelgaard; Laurence A Bindoff; Volker Straub; Hanns Lochmüller; Judith Hudson; Christoph M Wahl; Snjolaug Arnardottir; Kathe Dahlbom; Christoffer Jonsrud; Morten Duno
Journal:  Brain       Date:  2016-06-03       Impact factor: 13.501

9.  Calpain 3 is important for muscle regeneration: evidence from patients with limb girdle muscular dystrophies.

Authors:  Simon Hauerslev; Marie-Louise Sveen; Morten Duno; Corrado Angelini; John Vissing; Thomas O Krag
Journal:  BMC Musculoskelet Disord       Date:  2012-03-23       Impact factor: 2.362

10.  Natural history of LGMD2A for delineating outcome measures in clinical trials.

Authors:  Isabelle Richard; Jean-Yves Hogrel; Daniel Stockholm; Christine A M Payan; Françoise Fougerousse; Bruno Eymard; Claude Mignard; Adolfo Lopez de Munain; Michel Fardeau; Jon Andoni Urtizberea
Journal:  Ann Clin Transl Neurol       Date:  2016-03-04       Impact factor: 4.511

View more
  10 in total

1.  A novel CAPN3 mutation in late-onset limb-girdle muscular dystrophy with early respiratory insufficiency.

Authors:  Jennifer M Martinez-Thompson; Steven A Moore; Teerin Liewluck
Journal:  J Clin Neurosci       Date:  2018-04-21       Impact factor: 1.961

2.  Myopathy With SQSTM1 and TIA1 Variants: Clinical and Pathological Features.

Authors:  Zhiyv Niu; Carly Sabine Pontifex; Sarah Berini; Leslie E Hamilton; Elie Naddaf; Eric Wieben; Ross A Aleff; Kristina Martens; Angela Gruber; Andrew G Engel; Gerald Pfeffer; Margherita Milone
Journal:  Front Neurol       Date:  2018-03-19       Impact factor: 4.003

3.  Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients.

Authors:  Babi Ramesh Reddy Nallamilli; Samya Chakravorty; Akanchha Kesari; Alice Tanner; Arunkanth Ankala; Thomas Schneider; Cristina da Silva; Randall Beadling; John J Alexander; Syed Hussain Askree; Zachary Whitt; Lora Bean; Christin Collins; Satish Khadilkar; Pradnya Gaitonde; Rashna Dastur; Matthew Wicklund; Tahseen Mozaffar; Matthew Harms; Laura Rufibach; Plavi Mittal; Madhuri Hegde
Journal:  Ann Clin Transl Neurol       Date:  2018-12-01       Impact factor: 4.511

4.  The inflammatory pathology of dysferlinopathy is distinct from calpainopathy, Becker muscular dystrophy, and inflammatory myopathies.

Authors:  Nicole Becker; Steven A Moore; Karra A Jones
Journal:  Acta Neuropathol Commun       Date:  2022-02-08       Impact factor: 7.801

5.  Disease Progression and Mutation Pattern in a Large Cohort of LGMD R1/LGMD 2A Patients from India.

Authors:  Valakunja H Ganaraja; Kiran Polavarapu; Mainak Bardhan; Veeramani Preethish-Kumar; Shingavi Leena; Ram M Anjanappa; Seena Vengalil; Saraswati Nashi; Gautham Arunachal; Swetha Gunasekaran; Dhaarini Mohan; Sanita Raju; Gopikrishnan Unnikrishnan; Akshata Huddar; Valasani Ravi-Kiran; Priya T Thomas; Atchayaram Nalini
Journal:  Glob Med Genet       Date:  2021-11-09

6.  An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia.

Authors:  Chiara Gemelli; Monica Traverso; Lucia Trevisan; Sabrina Fabbri; Elena Scarsi; Barbara Carlini; Valeria Prada; Tiziana Mongini; Lucia Ruggiero; Serena Patrone; Salvatore Gallone; Rosa Iodice; Livia Pisciotta; Federico Zara; Paola Origone; Eugenia Rota; Carlo Minetti; Claudio Bruno; Angelo Schenone; Paola Mandich; Chiara Fiorillo; Marina Grandis
Journal:  Muscle Nerve       Date:  2021-11-08       Impact factor: 3.852

Review 7.  A Journey with LGMD: From Protein Abnormalities to Patient Impact.

Authors:  Dimitra G Georganopoulou; Vasilis G Moisiadis; Firhan A Malik; Ali Mohajer; Tanya M Dashevsky; Shirley T Wuu; Chih-Kao Hu
Journal:  Protein J       Date:  2021-06-10       Impact factor: 2.371

Review 8.  Calcium Mechanisms in Limb-Girdle Muscular Dystrophy with CAPN3 Mutations.

Authors:  Jaione Lasa-Elgarresta; Laura Mosqueira-Martín; Neia Naldaiz-Gastesi; Amets Sáenz; Adolfo López de Munain; Ainara Vallejo-Illarramendi
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

9.  Physiological aspects of muscular adaptations to training translated to neuromuscular diseases.

Authors:  Angela Berardinelli; Giuseppe D'Antona
Journal:  Acta Myol       Date:  2019-12-01

10.  Reply: Autosomal dominant segregation of CAPN3 c.598_612del15 associated with a mild form of calpainopathy.

Authors:  Babi Ramesh Reddy Nallamilli; Samya Chakravorty; Akanchha Kesari; Lora Bean; Madhuri Hegde
Journal:  Ann Clin Transl Neurol       Date:  2020-10-15       Impact factor: 5.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.